Product Program year 2025 Source: CMS Open Payments

Elrexfio

Drug Oncology

NDC 0069-2522-02

Open in the dashboard

General payments

$6,746,400

26,470 payments

Research payments

$63,998,609

3,833 payments

Through program year 2025, $6,746,400 in general payments and $63,998,609 in research payments were reported against Elrexfio (Oncology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

6 rows
Year Kind Amount Payments
2025 General $2,906,394 12,523
2025 Research $37,838,153 1,612
2024 General $3,321,881 11,660
2024 Research $15,000,237 1,114
2023 General $518,124 2,287
2023 Research $11,160,219 1,107

Breakdown

Who paid General payments · program years 2023–2025
  1. Pfizer Inc. $6,739,439 26,255 payments
  2. PBG Puerto Rico LLC $4,118 180 payments
  3. Array BioPharma Inc. $2,843 35 payments
Top recipients General payments · program year 2025
  1. Sanjeev Jain Hematology & Oncology · East Patchogue, NY $362,100 12% · 21 payments
  2. Marc Braunstein Allergy · Hewlett, NY $349,600 12% · 15 payments
  3. Shelbi Atrash Hematology & Oncology · Charlotte, NC $307,200 11% · 18 payments
  4. Parameswaran Hari Hematology & Oncology · Milwaukee, WI $282,000 10% · 18 payments
  5. Joseph Mikhael Hematology · Scottsdale, AZ $244,600 8% · 16 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Hematology & Oncology Internal Medicine $1,496,931 54% · 2,134 practitioners
  2. Hematology Internal Medicine $349,860 13% · 70 practitioners
  3. Allergy Allergy & Immunology $349,600 13% · 1 practitioner
  4. Diagnostic Radiology Radiology $197,175 7% · 9 practitioners
  5. Medical Oncology Internal Medicine $147,283 5% · 562 practitioners

The top 5 of 69 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. New York $791,468 27% · 261 recipients
  2. Massachusetts $452,001 16% · 27 recipients
  3. North Carolina $369,234 13% · 159 recipients
  4. Arizona $255,710 9% · 159 recipients
  5. California $231,061 8% · 550 recipients

The top 5 of 52 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Given in the clinic

Part B · billing code
Medicare Part B billing codes matched to ELREXFIO
Billing code Providers Services Paid by Medicare
Injection, elranatamab-bcmm, 1 mg J1323 2 5,588 $789,549

Drugs given by a clinician are billed to Medicare Part B, not Part D. The product is tied to a billing code through the NDC on CMS's crosswalk, which was published for a later quarter than the payments, so a code that changed in between can be missed. Providers with fewer than 11 patients for the code are not published. Medicare's payment here is what it paid for the services, to the billing practice.

26,470 general · 3,833 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record